A
Alexander James Bridges
Researcher at Pfizer
Publications - 94
Citations - 10058
Alexander James Bridges is an academic researcher from Pfizer. The author has contributed to research in topics: Tyrosine kinase & Epidermal growth factor. The author has an hindex of 38, co-authored 93 publications receiving 9894 citations. Previous affiliations of Alexander James Bridges include University of Auckland & Parke-Davis.
Papers
More filters
Journal ArticleDOI
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
TL;DR: Results indicate that the MAPK pathway is essential for growth and maintenance of the ras-transformed phenotype and PD 098059 is an invaluable tool that will help elucidate the role of theMAPK cascade in a variety of biological settings.
Journal ArticleDOI
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.
Judith Sebolt-Leopold,David T. Dudley,Roman Herrera,K Van Becelaere,A Wiland,Richard C. Gowan,Haile Tecle,Stephen Douglas Barrett,Alexander James Bridges,Sally A. Przybranowski,Wilbur R. Leopold,Alan R. Saltiel +11 more
TL;DR: The discovery of a highly potent and selective inhibitor of the upstream kinase MEK that is orally active is reported, indicating that MEK inhibitors represent a promising, noncytotoxic approach to the clinical management of colon cancer.
Journal ArticleDOI
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
David W. Fry,Alan J. Kraker,Amy McMichael,Linda A. Ambroso,James M. Nelson,Wilbur R. Leopold,Richard W. Connors,Alexander James Bridges +7 more
TL;DR: A small molecule called PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation.
Patent
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
Alexander James Bridges,William A. Denny,David W. Fry,Alan J. Kraker,Robert Frederick Meyer,Gordon W. Rewcastle,Andrew M. Thompson +6 more
TL;DR: In this paper, the authors considered the case where one of the two remaining atoms can be either carbon or nitrogen, and the ring structure was a fused 6,5 (5 or 6) tricycle.
Patent
Irreversible inhibitors of tyrosine kinases
Alexander James Bridges,William Alexander Denny,Ellen Myra Dobrusin,Annette Marian Doherty,David W. Fry,Dennis Joseph Mcnamara,Howard Daniel Hollis Showalter,Jeffrey Bruce Smaill,Zhou Hairong +8 more
TL;DR: In this article, a method for treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.